Prediabetes denotes glucose concentrations above the normal range but below the diagnostic threshold for type 2 diabetes. Adults with overweight and prediabetes are at increased risk of progression to type 2 diabetes and associated metabolic imbalance. Feiolix is a whole‑fruit feijoa powder formulated to deliver abscisic acid, polyphenols and dietary fiber, constituents proposed to support metabolic health through complementary pathways.
The objective of this randomized controlled trial was to evaluate the effects of low and high doses of Feiolix compared with placebo on HbA1c, glucagon‑like peptide‑1 (GLP‑1) and other metabolic parameters in adults with overweight and prediabetes.
This was a randomized, placebo‑controlled, parallel‑group study of adults aged 21–65 years with prediabetes defined by glycosylated hemoglobin (HbA1c 5.7–6.4%) and overweight (BMI 25.0–29.9 kg/m2). Forty‑one individuals were screened and 39 were randomized, with 13 participants assigned to each treatment arm. One participant withdrew from the Feiolix low‑dose group during the study period.
Anthropometric measurements were obtained monthly. Fasting blood samples and postprandial samples were collected at baseline and after 12 weeks of intervention.
Participants were randomized to one of three arms for 12 weeks:
The trial duration and dosing schedule were prespecified; additional formulation or manufacturing details beyond the constituents mentioned in the report were not provided.
Outcomes reported included HbA1c, GLP‑1, fasting plasma glucose, fasting insulin, insulin resistance estimated by HOMA‑IR, lipid markers (total cholesterol, LDL‑cholesterol, triglycerides), body weight and BMI.
Analyses were performed using an ANCOVA model with baseline values as covariates. The report presents between‑group comparisons versus placebo and notes statistical significance for several endpoints (p < 0.05 where indicated).
After 12 weeks, HbA1c decreased by 0.5% in the Feiolix high‑dose group and by 0.4% in the Feiolix low‑dose group. Both reductions were reported as significantly greater than placebo (p < 0.05). The absolute baseline and follow‑up HbA1c means and standard deviations were not included in the summary provided.
Compared with placebo, Feiolix supplementation significantly lowered fasting plasma glucose and fasting insulin. Estimates of insulin resistance using HOMA‑IR were also significantly reduced with Feiolix versus placebo. The report does not provide detailed numeric results for each arm beyond the statements of significance.
No between‑group change in GLP‑1 was observed; postprandial GLP‑1 concentrations did not differ between Feiolix and placebo at 12 weeks according to the summary.
Feiolix supplementation was associated with significant reductions in total cholesterol and LDL‑cholesterol compared with placebo. The Feiolix high‑dose arm specifically attenuated the increase in triglycerides that was observed in the placebo group over the 12‑week period. Exact concentrations, percent changes, and measures of variability were not reported in the abstract summary.
Participants randomized to the Feiolix high dose experienced significant reductions in body weight and BMI versus placebo by month 2. The low‑dose arm did not report similar anthropometric benefits in the summary. Specific weight change values and confidence intervals were not included in the provided text.
No treatment‑related adverse events were reported for either Feiolix dose during the 12‑week intervention. Tolerability findings beyond the absence of reported treatment‑related adverse events were not detailed in the summary.
The trial was registered under CTRI/2025/08/093439. Ethical approval was obtained from the Ethicare Ethics Committee, Mumbai Suburban (CDSCO registration no. ECR/224/Indt/MH/2015/RR‑21). The authors declared competing interests: one author was employed by the company that manufactures Feiolix at the time of the study, and two authors had been employed by a company that may receive royalties from Feiolix sales; these relationships were disclosed.
Datasets generated or analyzed during the study are available from the corresponding author on reasonable request.
This report is a medRxiv preprint and has not undergone peer review; the authors note this status. The summary provides statistically significant improvements in HbA1c, fasting glucose, fasting insulin, HOMA‑IR, total cholesterol and LDL‑cholesterol with Feiolix versus placebo, with additional body weight and BMI benefits at the higher dose and attenuation of triglyceride rise. No effect on GLP‑1 was observed.
The abstract does not include full numeric results for all endpoints, measures of variability, per‑protocol versus intention‑to‑treat analyses, or long‑term follow‑up data. Mechanistic biomarkers beyond the measured endpoints were not reported in the summary. The declared financial interests of several authors are relevant when interpreting the findings.
Overall, the trial supports the potential for Feiolix supplementation to improve several short‑term metabolic markers in adults with overweight and prediabetes, but these findings require peer review and independent replication before informing clinical practice.